Novel strategies for steroid-refractory acute graft-versus-host disease

Current Opinion in Hematology

Volumn 12, Issue 1, 2005, Pages 40-44

  Bolaños Meade, Javier ^a   Vogelsang, Georgia B ^b  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Acute graft versus host disease; Denileukin diftitox; Mycophenolate mofetil; Pentostatin; Steroid refractory graft versus host disease

Indexed keywords

ALEMTUZUMAB; DACLIZUMAB; DENILEUKIN DIFTITOX; INFLIXIMAB; METHOXSALEN; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; STEROID; THALIDOMIDE; THYMOCYTE ANTIBODY; VISILIZUMAB;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT RESPIRATORY DISTRESS SYNDROME; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHIMERA; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MESENCHYMAL STEM CELL; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; MYCOSIS; NAUSEA; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROGNOSIS; PUVA; REVIEW; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION; VOMITING;

ACUTE DISEASE; ANIMALS; ANTIBODIES, MONOCLONAL; BONE MARROW TRANSPLANTATION; DIPHTHERIA TOXIN; DRUG RESISTANCE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERLEUKIN-2; MYCOPHENOLIC ACID; PENTOSTATIN; PHOTOPHERESIS; RECOMBINANT FUSION PROTEINS; STEROIDS;

EID: 13244292532     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.moh.0000148763.12733.bb     Document Type: Review

References (29)

1. Billingham RE: The biology of graft-versus-host reactions. Harvey Lect 1966, 62:21-78.
2. Ferrara JL, Cooke KR, Teshima T: The pathophysiology of acute graft-versus-host disease. Int J Hematol 2003, 78:181-187. An excellent review of the biology of aGVHD.
3. Hurley CK, Baxter Lowe LA, Logan B, et al.: National Marrow Donor Program HLA-matching guidelines for unrelated marrow transplants. Biol Blood Marrow Transplant 2003, 9:610-615. This paper outlines the recommendations of the National Marrow Donor Program for HLA matching to prevent GVHD and other complications.
4. Deleted in proof.
5. Akatsuka Y, Warren EH, Gooley TA, et al.: Disparity for a newly identified minor histocompatibility antigen, HA-8, correlates with acute graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling. Br J Haematol 2003, 123:671-675. This paper discusses the role of a newly identified mHA molecule in the development of GVHD.
6. Mullighan C, Heatley S, Doherty K, et al.: Non-HLA immunogenetic polymorphisms and the risk of complications after allogeneic hemopoietic stem-cell transplantation. Transplantation 2004, 77:587-596. This study describes how different genetic polymorphisms carry different risks for developing GVHD.
7. Lin MT, Storer B, Martin PJ, et al.: Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 2003, 349:2201-2210. This paper analyzes single-nucleotide polymorphisms in the genes for IL-1 b, IL-1 receptor antagonist, IL-6, and IL-10 and their relationship with aGVHD.
8. Jordan WJ, Brookes PA, Szydlo RM, et al.: IL-13 production by donor T cells is prognostic of acute graft-versus-host disease following unrelated donor stem cell transplantation. Blood 2004, 103:717-724. Interesting study correlating levels of IL-13 with the development of aGVHD.
9. Arai S, Klingemann HG: Hematopoietic stem cell transplantation: bone marrow vs. mobilized peripheral blood. Arch Med Res 2003, 34:545-553. This excellent review discusses the benefits of using different sources of stem cells, either BM or PSCs.
10. Ringden O, Labopin M, Gorin NC, et al.: Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2004, 22:416-423. An interesting trial describing a new side effect of growth factors on patients undergoing allogeneic SCT.
11. Jacobsohn DA, Duerst R, Tse W, Kletzel M: Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children. Lancet 2004, 364:156-162. A very elegant study on the use of nonmyeloablative stem cells for nonmalignant conditions in children, with description of side effects.
12. Arai S, Margolis J, Zahurak M, et al.: Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 2002, 8:155-160.
13. Carpenter PA, Appelbaum FR, Corey L, et al.: A humanized non-FcR-binding anti-CD3 antibody, visifeumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 2002, 99:2712-2719.
14. Jacobsohn DA, Hallick J, Anders V, et al.: Infliximab for steroid-refractory acute GVHD: a case series. Am J Hematol 2003, 74:119-124. Case series from patients treated with infliximab for steroid-refractory aGVHD.
15. Couriel D, Saliba R, Hicks K, et al.: Tumor necrosis factor-a blockade for the treatment of acute GVHD. Blood 2004, 104:649-654. Interesting study on patients receiving infliximab for steroid-refractory aGVHD.
16. Yamane T, Yamamura R, Aoyama Y, et al.: Infliximab for the treatment of severe steroid refractory acute graft-versus-host disease in three patients after allogeneic hematopoietic transplantation. Leuk Lymphoma 2003, 44:2095-2097. Case series from patients treated with infliximab for steroid-refractory aGVHD.
17. Marty FM, Lee SJ, Fahey MM, et al.: Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003, 102:2768-2776. This interesting report discusses the risk of developing invasive fungal infections in patients receiving infliximab.
18. Carella AM, Beltrami G, Scalzulli PR, et al.: Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (aGVHD). Bone Marrow Transplant 2004, 33:131-132. Interesting case reports from patients treated with alemtuzumab for steroidrefractory aGVHD.
19. Srinivasan R, Chakrabarti S, Walsh T, et al.: Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis. Br J Haematol 2004, 124:777-786. Interesting study on patients receiving daclizumab for steroid-refractory aGVHD.
20. Lee SJ, Zahrieh D, Agura E, et al.: Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 2004, 104:1559-1564. Very interesting study comparing double therapy with steroids and daclizumab vs steroids alone in patients with aGVHD.
21. Ho VT, Zahrieh D, Hochberg E, et al.: Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2004, 104:1224-1226. Elegant study reporting the results of the use of denileukin diftitox in patients with steroid-refractory aGVHD.
22. Kim JG, Sohn SK, Kim DH, et al.: Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. Eur J Haematol 2004, 73:56-61. This study describes the effect of mycophenolate mofetil in patients with steroid-refractory aGVHD.
23. Miyoshi T, Kawano-Yamamoto C, Nagashima T, et al.: Successful treatment of refractory acute GVHD with mycophenolate mofetil after peripheral blood stem cell transplantation from the patient's one locus-mismatched mother. Rinsho Ketsueki 2003, 44:968-970.
24. Bolaños-Meade J, Jacobsohn D, Margolis J, et al.: Pentostatin in steroid refractory acute graft versus host disease. Blood 2002, 100:420A.
25. Salvaneschi L, Perotti C, Zecca M, et al.: Extracorporeal photochemotherapy for treatment of acute and chronic GVHD in childhood. Transfusion 2001, 41:1299-1305.
26. Le Blanc K, Tammik L, Sundberg B, et al.: Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003, 57:11-20.
27. Le Blanc K, Rasmusson I, Sundberg B, et al: Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441. Very interesting report on the use of haploidentical mesenchymal stem cells as therapy for a child with steroid-refractory GVHD.
28. Kulkarni S, Powles R, Sirohi B, et al.: Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. Bone Marrow Transplant 2003, 32:165-170. This paper describes the reasons thalidomide should not be used for the treatment of aGVHD.
29. Nakai K, Tajima K, Tanigawa N, et al.: Intra-arterial steroid-injection therapy for steroid-refractory acute graft-versus-host disease with the evaluation of angiography. Bone Marrow Transplant 2004, 33:1231-1233. This report on three patients receiving intra-arterial steroids for the treatment of aGVHD describes the potential use of this approach for the treatment of steroid-refractory disease.